Larvol Delta - SCOPE-Plus-iSCIB1-in-Combination-With-Ipilimumab-and-Nivolumab-as-FirstLine-Treatment-for-Advanced-Unresectable-Melanoma

iSCIB1+ - Scancell

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

http://clinicaltrials.gov/ct2/show/NCT07815574

Sep 12, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next